Decreased myofibroblasts in the peritumoral region and high expression of MMP-7 in Pan02 S.C. tumor of <i>S100a4-Cre; Ext1</i>^<i>f/f</i> mice. by Ayumi Niwa (6256790)

“…Alcian blue staining (pH = 2.5) in the peritumoral region of Pan02 S.C. pancreatic tumors in <i>S100a4-Cre; Ext1</i>^<i>f/f</i> and control mice (middle). …”

Five compounds significantly decrease MAPK1 phosphorylation in K562 cells. by Pamela Y. Ting (713174)

LY5 does not inhibit growth of <i>ex vivo</i> pulmonary metastasis. by Peter Y. Yu (4281448)

Mean pain interference overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Mean pain severity overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

Astrocytic AQP4 is decreased in aged cortical astrocytes. by Ileana Soto (531878)

“…**<i>p</i> < 0.005 (B) by unpaired <i>t</i> test. Scale Bars: 50 μm (A and C) and 2 μm (D). DP = degenerated pericyte, EC = endothelial cell and BV = blood vessel. …”

Average step length and frequency (± SEM) per 5% of the distance during normal and 3, 4, and 5 kg assisted 60 m sprints for men and women. by Roland van den Tillaar (6407390)

Blocking C5L2 decreased C5a-primed neutrophils for ANCA-induced respiratory burst. by Jian Hao (160736)

AA-deficient <i>sfx</i> mice had decreased articular cartilage. by Richard C. Lindsey (7148168)

Type and duration of leisure-time activities performed 5 years after RYGB. by Alice Bellicha (3583493)

An example of three consecutive accretive growth steps. by Nol Chindapol (103374)

Means and Cronbach’s alphas for 5C and VAX-measured vaccination attitudes over 12 months. by Allyson J. Gallant (9382396)

Inflammatory conditions decrease CD36 expression and CD36-mediated <i>Pf</i>PEs phagocytosis through downregulation of PPARγ. by David Olagnier (205583)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects: